|
R&D Pipeline News Vol. 2, Issue 17: Syk kinase Inhibitors |
|
|
|
08 May 2006 |
Read the highlights of the most recent edition of our weekly R&D information product R&D Pipeline News. The Special Product or Technology Pipelines of R&D Pipeline News are available via subscription of R&D Pipeline News or as a single Project Pipeline List .
 |
| |
Special Pipeline:
Featured Company Pipelines
|
Vol. 2 Issue nº 17
May 08, 2006
|
 |
|
|
Special Pipeline
|
Syk kinase Inhibitors
|
- New treatment modality siRNA silencing the syk kinase gene;
- New indication focus on asthma via inhalation;
- Phase I/II study with oral small molecule in rheumatoid arthritis;
- Potential safety risks at long term use
|
|
|
Featured Company Pipelines
|
Incyte Corporation
|
- CCR2 antagonist program shared with Pfizer;
- Own CCR2 project in multiple sclerosis;
- Sheddase inhibitor in phase I/II for cancer;
- IND-stage projects for HIV and diabetes
-
|
Astex Therapeutics
|
- Proprietary fragment-based drug discovery technology;
- Therapeutic focus on oncology;
- Shared CDK-inhibitor programs with Novartis;
- IND-stage for own aurora kinase inhibitor;
- Numerous lead compounds under optimization
|
Oxford BioMedica
|
- Proprietary technology for lentiviral vector delivery of plasmids;
- Two inhouse oncology projects in phase II;
- Immunotoxin project with Wyeth to enter phase I in 2006;
- Numerous preclinical gene therapy projects available for co-development
|
Oxxon Therapeutics
|
- Proprietary vaccine technology of DNA plasmid boost followed by prime with non-replicating MVA vector;
- Phase II projects in HBV and melanoma;
- Follow-on projects in preclinical stage;
- HIV application targeting multiple antigen and epitopes
|
|
R&D Pipeline News
Get your Subscription Now
|
R&D Pipeline News is a premier information source about research and development (R&D) projects in the pipeline of the biopharmaceutical industry and is directed to all stakeholders in R&D . R&D Pipeline News covers all relevant treatment modalities, including. drugs, medical devices, biomaterials, combination products, cell therapy and drug delivery products.
Read more about R&D Pipeline NewsOrder Now
 
|
|
|
|
|
|
|
|
|
